Free Trial
→ Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps (From Weiss Ratings) (Ad) Buy KYMR Stock  Free KYMR Stock Alerts

Kymera Therapeutics (KYMR) Financials

Kymera Therapeutics logo
$25.46 +0.03 (+0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$25.48 +0.02 (+0.08%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Kymera Therapeutics

Annual Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -41 -55 -100 -155 -147 -224
Consolidated Net Income / (Loss)		 -41 -46 -100 -155 -147 -224
Net Income / (Loss) Continuing Operations		 -40 -46 -100 -155 -147 -224
Total Pre-Tax Income 		-41 -46 -100 -155 -147 -224
Total Operating Income		 -42 -46 -101 -161 -166 -262
Total Gross Profit		 2.93 34 73 47 79 47
Total Revenue		 2.93 34 73 47 79 47
Operating Revenue		 2.93 34 73 47 79 47
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 45 80 173 208 244 309
Selling, General & Admin Expense		 7.98 18 36 44 55 64
Research & Development Expense		 37 62 137 164 189 240
Impairment Charge		 - - - 0.00 0.00 4.93
Total Other Income / (Expense), net		 0.96 0.71 0.31 6.45 19 38
Other Income / (Expense), net		 0.96 0.71 0.31 6.45 19 38
Basic Earnings per Share		 ($24.28) ($3.15) ($2.09) ($2.87) ($2.52) ($2.98)
Weighted Average Basic Shares Outstanding		 1.70M 17.35M 47.99M 53.93M 58.37M 75.04M
Diluted Earnings per Share		 ($24.28) ($3.15) ($2.09) ($2.87) ($2.52) ($2.98)
Weighted Average Diluted Shares Outstanding		 1.70M 17.35M 47.99M 53.93M 58.37M 75.04M
Weighted Average Basic & Diluted Shares Outstanding		 1.70M 17.35M 47.99M 55.18M 61.11M 64.94M

Quarterly Income Statements for Kymera Therapeutics

This table shows Kymera Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Consolidated Net Income / (Loss)		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Net Income / (Loss) Continuing Operations		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Total Pre-Tax Income 		-43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Total Operating Income		 -45 -39 -45 -43 -58 -19 -58 -51 -72 -81
Total Gross Profit		 9.55 16 9.47 17 4.73 48 10 26 3.74 7.39
Total Revenue		 9.55 16 9.47 17 4.73 48 10 26 3.74 7.39
Operating Revenue		 9.55 16 9.47 17 4.73 48 10 26 3.74 7.39
Total Operating Expenses		 54 55 55 60 62 67 68 77 76 88
Selling, General & Admin Expense		 11 12 13 14 14 14 14 17 15 16
Research & Development Expense		 44 43 42 46 48 53 49 59 60 72
Total Other Income / (Expense), net		 1.88 3.77 4.40 4.58 4.64 4.94 9.27 8.86 9.64 10
Other Income / (Expense), net		 1.88 3.77 4.40 4.58 4.64 4.94 9.27 8.86 9.64 10
Basic Earnings per Share		 ($0.79) ($0.59) ($0.70) ($0.67) ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89)
Weighted Average Basic Shares Outstanding		 54.54M 53.93M 58.19M 58.33M 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M
Diluted Earnings per Share		 ($0.79) ($0.59) ($0.70) ($0.67) ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89)
Weighted Average Diluted Shares Outstanding		 54.54M 53.93M 58.19M 58.33M 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M
Weighted Average Basic & Diluted Shares Outstanding		 54.86M 55.18M 55.31M 55.41M 55.49M 61.11M 61.36M 61.75M 64.77M 64.94M

Annual Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 36 -45 21 20 41 10
Net Cash From Operating Activities		 18 88 -129 -153 -103 -195
Net Cash From Continuing Operating Activities		 18 88 -129 -153 -103 -195
Net Income / (Loss) Continuing Operations		 -41 -46 -100 -155 -147 -224
Consolidated Net Income / (Loss)		 -41 -46 -100 -155 -147 -224
Depreciation Expense		 0.83 1.76 2.40 2.98 3.57 7.37
Non-Cash Adjustments To Reconcile Net Income		 1.64 6.24 32 34 37 49
Changes in Operating Assets and Liabilities, net		 57 126 -63 -36 3.91 -27
Net Cash From Investing Activities		 -16 -423 -100 21 140 -404
Net Cash From Continuing Investing Activities		 -16 -423 -100 21 140 -404
Purchase of Property, Plant & Equipment		 -0.53 -9.10 -1.60 -2.84 -34 -13
Purchase of Investments		 -16 -529 -456 -446 -189 -901
Sale and/or Maturity of Investments		 0.00 116 358 469 364 510
Net Cash From Financing Activities		 35 289 250 153 4.19 609
Net Cash From Continuing Financing Activities		 35 289 250 153 4.19 609
Repayment of Debt		 -0.37 -0.55 -0.85 -1.13 -0.08 -1.58
Issuance of Common Equity		 0.00 183 0.79 153 2.86 12
Other Financing Activities, net		 0.07 14 9.98 1.15 1.41 599
Cash Interest Paid		 0.05 0.12 0.16 0.18 0.16 0.21

Quarterly Cash Flow Statements for Kymera Therapeutics

This table details how cash moves in and out of Kymera Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 79 -87 -18 1.89 29 29 -16 -26 43 9.55
Net Cash From Operating Activities		 -34 -40 -44 -35 -32 8.05 -40 -43 -50 -62
Net Cash From Continuing Operating Activities		 -35 -40 -44 -35 -32 8.05 -40 -43 -50 -62
Net Income / (Loss) Continuing Operations		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Consolidated Net Income / (Loss)		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Depreciation Expense		 0.77 0.82 0.88 0.90 0.90 0.89 1.46 1.94 1.99 1.99
Non-Cash Adjustments To Reconcile Net Income		 7.88 8.87 7.28 8.96 11 9.64 16 10 14 9.02
Changes in Operating Assets and Liabilities, net		 -0.29 -14 -11 -6.32 9.54 12 -8.67 -13 -3.24 -2.04
Net Cash From Investing Activities		 -37 -50 25 36 61 19 -331 16 -158 69
Net Cash From Continuing Investing Activities		 -37 -50 25 36 61 19 -331 16 -158 69
Purchase of Property, Plant & Equipment		 -1.25 -0.37 -4.01 -11 -8.08 -12 -7.40 -4.69 0.19 -0.94
Purchase of Investments		 -154 -147 -62 -53 -29 -46 -423 -104 -296 -78
Sale and/or Maturity of Investments		 118 98 90 99 98 76 99 124 138 148
Net Cash From Financing Activities		 150 1.95 1.16 1.31 -0.21 1.93 354 1.41 251 2.77
Net Cash From Continuing Financing Activities		 150 1.95 1.16 1.31 -0.21 1.93 354 0.28 252 2.77
Repayment of Debt		 -0.29 -0.31 -0.33 -0.33 -0.34 0.93 -0.29 -0.35 -0.64 -0.29
Issuance of Common Equity		 150 2.90 1.49 0.68 0.13 0.56 305 0.63 252 -546
Other Financing Activities, net		 0.96 -0.64 0.00 0.96 - 0.45 49 - 1.13 549
Cash Interest Paid		 0.04 0.06 0.05 0.03 0.04 0.05 0.05 0.04 0.05 0.06

Annual Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Total Assets		 117 487 606 603 576 978
Total Current Assets		 93 302 451 419 405 510
Cash & Equivalents		 76 31 48 68 110 120
Short-Term Investments		 16 265 394 339 265 368
Accounts Receivable		 0.00 0.58 0.00 0.00 15 0.00
Prepaid Expenses		 0.89 4.70 8.72 9.71 12 21
Other Current Assets		 0.00 0.86 0.14 2.54 3.76 0.95
Plant, Property, & Equipment, net		 3.79 11 12 13 48 50
Total Noncurrent Assets		 20 174 143 170 122 417
Long-Term Investments		 0.00 163 125 152 61 362
Other Noncurrent Operating Assets		 20 11 18 18 61 55
Total Liabilities & Shareholders' Equity		 117 487 606 603 576 978
Total Liabilities		 82 203 146 113 181 142
Total Current Liabilities		 35 111 93 71 86 68
Accounts Payable		 3.28 4.37 4.01 4.34 7.08 5.99
Accrued Expenses		 4.57 10 23 28 34 35
Current Deferred Revenue		 23 93 62 35 38 14
Other Current Liabilities		 3.38 3.37 3.83 4.25 6.87 13
Total Noncurrent Liabilities		 47 93 54 42 95 75
Noncurrent Deferred Revenue		 30 78 39 28 17 0.00
Other Noncurrent Operating Liabilities		 18 15 14 14 78 75
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -74 284 460 490 395 836
Total Preferred & Common Equity		 -74 284 460 490 395 836
Total Common Equity		 -74 284 460 490 395 836
Common Stock		 2.04 413 689 879 926 1,592
Retained Earnings		 -76 -129 -229 -384 -531 -755
Accumulated Other Comprehensive Income / (Loss)		 0.01 -0.13 -0.66 -4.95 -0.55 -1.49

Quarterly Balance Sheets for Kymera Therapeutics

This table presents Kymera Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 638 614 582 552 868 826 1,035
Total Current Assets		 494 412 385 376 537 525 569
Cash & Equivalents		 156 50 52 81 94 68 111
Short-Term Investments		 326 347 315 277 427 442 439
Accounts Receivable		 - - - - 0.00 0.00 0.00
Prepaid Expenses		 9.23 11 14 14 15 14 17
Other Current Assets		 2.88 3.32 4.12 3.78 2.03 1.70 1.32
Plant, Property, & Equipment, net		 13 17 27 36 49 52 51
Total Noncurrent Assets		 132 185 169 141 282 249 415
Long-Term Investments		 114 119 105 77 224 192 361
Other Noncurrent Operating Assets		 18 66 64 64 57 56 54
Total Liabilities & Shareholders' Equity		 638 614 582 552 868 826 1,035
Total Liabilities		 126 152 147 157 157 141 142
Total Current Liabilities		 91 62 55 63 56 62 67
Accounts Payable		 6.33 6.48 3.75 4.98 6.81 6.51 6.49
Accrued Expenses		 25 19 22 26 16 24 27
Current Deferred Revenue		 56 32 24 27 23 19 20
Other Current Liabilities		 4.33 4.70 4.07 4.45 11 13 13
Total Noncurrent Liabilities		 34 90 92 94 101 79 75
Noncurrent Deferred Revenue		 21 25 20 16 24 3.19 0.00
Other Noncurrent Operating Liabilities		 13 65 71 77 77 76 75
Total Equity & Noncontrolling Interests		 513 462 435 396 711 685 893
Total Preferred & Common Equity		 513 462 435 396 711 685 893
Total Common Equity		 513 462 435 396 711 685 893
Common Stock		 868 890 903 914 1,292 1,308 1,575
Retained Earnings		 -349 -425 -464 -516 -579 -621 -684
Accumulated Other Comprehensive Income / (Loss)		 -5.91 -3.04 -3.64 -2.45 -1.78 -2.10 1.93

Annual Metrics and Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 1,059.99% 114.00% -35.71% 67.84% -40.11%
EBITDA Growth		 0.00% -8.43% -123.18% -55.21% 5.55% -50.97%
EBIT Growth		 0.00% -10.54% -119.81% -54.47% 5.07% -52.32%
NOPAT Growth		 0.00% -9.71% -117.11% -60.41% -2.65% -58.06%
Net Income Growth		 0.00% -10.54% -119.81% -54.47% 5.07% -52.32%
EPS Growth		 0.00% 87.03% 33.65% -37.32% 12.20% -18.25%
Operating Cash Flow Growth		 0.00% 392.21% -246.31% -18.72% 32.83% -89.16%
Free Cash Flow Firm Growth		 0.00% 0.00% -261.19% -10.39% 5.04% -45.41%
Invested Capital Growth		 0.00% -205.23% 38.25% 35.77% 40.38% 63.03%
Revenue Q/Q Growth		 0.00% 0.00% 3.54% 1.88% 67.77% -46.24%
EBITDA Q/Q Growth		 0.00% 0.00% -27.58% -0.47% 12.55% -34.30%
EBIT Q/Q Growth		 0.00% 0.00% -27.05% -0.55% 12.24% -33.67%
NOPAT Q/Q Growth		 0.00% 0.00% -26.74% -2.96% 10.45% -30.69%
Net Income Q/Q Growth		 0.00% 0.00% -26.85% -0.63% 12.24% -33.67%
EPS Q/Q Growth		 0.00% 0.00% -116.02% 3.37% 11.89% -27.35%
Operating Cash Flow Q/Q Growth		 0.00% -9.51% -16.52% -0.78% 31.63% -56.01%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 2.16% 16.76% -29.67%
Invested Capital Q/Q Growth		 0.00% 0.00% 15.61% 16.18% -5.26% 15.44%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,377.68% -128.78% -134.31% -324.25% -182.46% -459.90%
Operating Margin		 -1,438.48% -136.05% -138.03% -344.37% -210.62% -555.82%
EBIT Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57%
Profit (Net Income) Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -118.95% -28.62% -26.96% -32.60% -33.21% -36.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -35.34% -15.10% -18.34% -25.61% -24.93% -28.81%
Return on Assets (ROA)		 -35.34% -15.10% -18.34% -25.61% -24.93% -28.81%
Return on Common Equity (ROCE)		 255.26% -18.82% -26.96% -32.60% -33.21% -36.38%
Return on Equity Simple (ROE_SIMPLE)		 55.43% -16.06% -21.80% -31.58% -37.21% -26.79%
Net Operating Profit after Tax (NOPAT)		 -30 -32 -70 -113 -116 -183
NOPAT Margin		 -1,006.94% -95.24% -96.62% -241.06% -147.43% -389.07%
Net Nonoperating Expense Percent (NNEP)		 -12.73% -4.79% -5.82% -7.44% -6.24% -6.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -23.03% -29.34% -21.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 272.02% 53.57% 49.90% 93.61% 70.03% 134.97%
R&D to Revenue		 1,266.46% 182.48% 188.13% 350.76% 240.59% 510.38%
Operating Expenses to Revenue		 1,538.48% 236.05% 238.03% 444.37% 310.62% 655.82%
Earnings before Interest and Taxes (EBIT)		 -41 -46 -100 -155 -147 -224
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -44 -98 -152 -143 -216
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 9.71 7.10 2.79 3.58 3.12
Price to Tangible Book Value (P/TBV)		 0.00 9.71 7.10 2.79 3.58 3.12
Price to Revenue (P/Rev)		 42.64 80.99 44.80 29.24 17.98 55.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 48.48 67.51 37.00 17.30 12.42 37.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 7.94 26.07 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 26.98 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -2.65 -1.73 -1.38 -1.19 -1.13 -1.05
Leverage Ratio		 3.37 1.90 1.47 1.27 1.33 1.26
Compound Leverage Factor		 3.37 1.90 1.47 1.27 1.33 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 314.59% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -214.59% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.54 8.00 13.14 6.30 3.36 9.73
Noncontrolling Interest Sharing Ratio		 314.59% 34.24% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 2.69 2.73 4.88 5.88 4.73 7.53
Quick Ratio		 2.66 2.68 4.78 5.71 4.55 7.21
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 85 -137 -152 -144 -209
Operating Cash Flow to CapEx		 3,365.60% 968.89% -8,074.26% -5,397.92% -298.22% -1,515.04%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.03 0.11 0.13 0.08 0.13 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.77 4.65 6.41 3.71 2.56 0.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -57 -175 -108 -69 -41 -15
Invested Capital Turnover		 -0.05 -0.29 -0.52 -0.53 -1.42 -1.66
Increase / (Decrease) in Invested Capital		 0.00 -118 67 39 28 26
Enterprise Value (EV)		 142 2,298 2,695 810 976 1,755
Market Capitalization		 125 2,756 3,263 1,369 1,413 2,606
Book Value per Share		 ($43.81) $6.39 $8.94 $8.93 $7.12 $12.90
Tangible Book Value per Share		 ($43.81) $6.39 $8.94 $8.93 $7.12 $12.90
Total Capital		 35 284 460 490 395 836
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -92 -459 -568 -559 -436 -851
Capital Expenditures (CapEx)		 0.53 9.10 1.60 2.84 34 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -34 -104 -84 -59 -55 -46
Debt-free Net Working Capital (DFNWC)		 58 192 359 348 320 443
Net Working Capital (NWC)		 58 192 359 348 320 443
Net Nonoperating Expense (NNE)		 12 13 30 42 31 41
Net Nonoperating Obligations (NNO)		 -92 -459 -568 -559 -436 -851
Total Depreciation and Amortization (D&A)		 0.83 1.76 2.40 2.98 3.57 7.37
Debt-free, Cash-free Net Working Capital to Revenue		 -1,147.99% -306.99% -114.90% -126.20% -70.31% -98.24%
Debt-free Net Working Capital to Revenue		 1,986.20% 563.32% 492.55% 743.33% 406.69% 940.05%
Net Working Capital to Revenue		 1,986.20% 563.32% 492.55% 743.33% 406.69% 940.05%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($3.15) ($2.09) ($2.87) ($2.52) ($2.98)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 44.81M 51.70M 53.93M 58.37M 75.04M
Adjusted Diluted Earnings per Share		 $0.00 ($3.15) ($2.09) ($2.87) ($2.52) ($2.98)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 44.81M 51.70M 53.93M 58.37M 75.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.15) ($2.09) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.35M 47.99M 55.18M 61.11M 64.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -32 -70 -113 -116 -180
Normalized NOPAT Margin		 -1,006.94% -95.24% -96.62% -241.06% -147.43% -381.75%
Pre Tax Income Margin		 -1,405.79% -133.96% -137.60% -330.60% -186.99% -475.57%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Kymera Therapeutics

This table displays calculated financial ratios and metrics derived from Kymera Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -53.03% 5.66% -1.62% 43.42% -50.50% 196.70% 8.67% 55.33% -20.88% -84.56%
EBITDA Growth		 -51.62% -2.13% -11.26% 4.18% -23.05% 60.42% -17.60% -5.87% -16.41% -410.24%
EBIT Growth		 -50.74% -2.47% -11.57% 3.62% -22.94% 58.79% -18.64% -8.41% -18.20% -392.43%
NOPAT Growth		 -56.73% -13.64% -22.72% -6.30% -28.13% 50.01% -27.59% -17.38% -25.41% -318.16%
Net Income Growth		 -50.45% -2.85% -11.57% 3.62% -22.94% 58.79% -18.64% -8.41% -18.20% -392.43%
EPS Growth		 -41.07% 14.49% 1.41% 14.10% -13.92% 57.63% 1.43% 13.43% 8.89% -256.00%
Operating Cash Flow Growth		 8.03% -3.09% -9.12% 9.57% 7.65% 120.35% 9.96% -21.78% -58.59% -867.98%
Free Cash Flow Firm Growth		 2.65% 27.58% 20.61% 13.65% -9.22% 36.77% 16.25% 29.39% 14.35% -98.93%
Invested Capital Growth		 35.34% 35.77% 43.02% 56.35% 52.52% 40.38% 37.41% 52.65% 53.98% 63.03%
Revenue Q/Q Growth		 -17.05% 68.98% -41.35% 74.45% -71.37% 912.80% -78.52% 149.34% -85.42% 97.65%
EBITDA Q/Q Growth		 -6.78% 19.39% -17.63% 5.37% -37.13% 74.07% -249.45% 14.80% -50.78% -13.66%
EBIT Q/Q Growth		 -6.82% 18.92% -17.39% 5.20% -36.26% 72.82% -237.95% 13.38% -48.56% -13.23%
NOPAT Q/Q Growth		 -9.98% 13.93% -17.33% 4.29% -32.56% 66.42% -199.46% 11.94% -41.63% -11.97%
Net Income Q/Q Growth		 -6.82% 18.92% -17.39% 5.20% -36.26% 72.82% -237.95% 13.38% -48.56% -13.23%
EPS Q/Q Growth		 -1.28% 25.32% -18.64% 4.29% -34.33% 72.22% -176.00% 15.94% -41.38% -8.54%
Operating Cash Flow Q/Q Growth		 12.10% -15.37% -11.21% 19.81% 10.24% 125.42% -592.12% -8.45% -16.89% -23.10%
Free Cash Flow Firm Q/Q Growth		 15.16% 14.32% -10.27% -7.73% -7.31% 50.40% -46.06% 9.17% -30.16% -15.20%
Invested Capital Q/Q Growth		 2.15% 16.18% 22.29% 31.52% -6.43% -5.26% 18.41% 48.20% -3.44% 15.44%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -442.21% -210.96% -423.08% -229.51% -1,099.24% -28.14% -457.82% -156.43% -1,617.21% -930.01%
Operating Margin		 -469.92% -239.36% -478.83% -262.72% -1,216.35% -40.33% -562.18% -198.54% -1,927.93% -1,092.17%
EBIT Margin		 -450.24% -216.03% -432.37% -234.96% -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88%
Profit (Net Income) Margin		 -450.24% -216.03% -432.37% -234.96% -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.89% -32.60% -35.71% -37.82% -36.87% -33.21% -26.35% -28.18% -26.00% -36.38%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -32.31% -16.73% -34.29% -21.97% -87.97% -4.00% -50.58% -20.63% -184.30% -57.98%
Return on Assets (ROA)		 -32.31% -16.73% -34.29% -21.97% -87.97% -4.00% -50.58% -20.63% -184.30% -57.98%
Return on Common Equity (ROCE)		 -30.89% -32.60% -35.71% -37.82% -36.87% -33.21% -26.35% -28.18% -26.00% -36.38%
Return on Equity Simple (ROE_SIMPLE)		 -30.00% 0.00% -34.43% -36.19% -42.34% 0.00% -21.74% -23.05% -18.76% 0.00%
Net Operating Profit after Tax (NOPAT)		 -31 -27 -32 -30 -40 -14 -40 -36 -50 -57
NOPAT Margin		 -328.94% -167.56% -335.18% -183.90% -851.44% -28.23% -393.52% -138.98% -1,349.55% -764.52%
Net Nonoperating Expense Percent (NNEP)		 -1.92% -1.39% -1.77% -1.77% -2.45% -0.17% -1.28% -1.09% -1.78% -2.21%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.52% - - - -3.42% - - - -6.76%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 110.52% 72.10% 132.74% 85.56% 298.65% 29.71% 139.73% 67.73% 413.12% 220.88%
R&D to Revenue		 459.40% 267.27% 446.09% 277.16% 1,017.70% 110.62% 474.57% 230.81% 1,614.81% 971.29%
Operating Expenses to Revenue		 569.92% 339.36% 578.83% 362.72% 1,316.35% 140.33% 662.18% 298.54% 2,027.93% 1,192.17%
Earnings before Interest and Taxes (EBIT)		 -43 -35 -41 -39 -53 -14 -49 -42 -62 -71
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -34 -40 -38 -52 -13 -47 -40 -61 -69
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.20 2.79 3.54 2.92 1.95 3.58 3.14 2.67 3.27 3.12
Price to Tangible Book Value (P/TBV)		 2.20 2.79 3.54 2.92 1.95 3.58 3.14 2.67 3.27 3.12
Price to Revenue (P/Rev)		 24.57 29.24 35.04 24.61 16.44 17.98 28.09 20.68 33.38 55.35
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 11.61 17.30 23.98 15.47 7.16 12.42 18.71 12.75 22.98 37.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.21 -1.19 -1.17 -1.15 -1.13 -1.13 -1.07 -1.05 -1.04 -1.05
Leverage Ratio		 1.29 1.27 1.32 1.33 1.31 1.33 1.26 1.26 1.23 1.26
Compound Leverage Factor		 1.29 1.27 1.32 1.33 1.31 1.33 1.26 1.26 1.23 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.24 6.96 6.03 4.64 2.09 4.12 8.16 7.35 11.90 10.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 5.42 5.88 6.65 7.06 5.95 4.73 9.57 8.45 8.55 7.53
Quick Ratio		 5.29 5.71 6.41 6.73 5.66 4.55 9.27 8.21 8.27 7.21
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -77 -66 -72 -78 -84 -42 -61 -55 -72 -83
Operating Cash Flow to CapEx		 -2,750.32% -10,599.46% -1,096.73% -327.41% -391.77% 69.20% -534.87% -915.68% 0.00% -6,600.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.07 0.08 0.08 0.09 0.08 0.13 0.11 0.13 0.11 0.06
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.71 3.71 3.20 2.57 1.92 2.56 2.38 2.24 2.00 0.95
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -83 -69 -54 -37 -39 -41 -34 -17 -18 -15
Invested Capital Turnover		 -0.44 -0.53 -0.63 -0.85 -0.77 -1.42 -1.81 -3.26 -3.05 -1.66
Increase / (Decrease) in Invested Capital		 45 39 41 48 43 28 20 19 21 26
Enterprise Value (EV)		 533 810 1,119 799 335 976 1,486 1,129 2,012 1,755
Market Capitalization		 1,129 1,369 1,635 1,272 770 1,413 2,231 1,832 2,923 2,606
Book Value per Share		 $9.89 $8.93 $8.37 $7.87 $7.14 $7.12 $10.05 $11.16 $14.46 $12.90
Tangible Book Value per Share		 $9.89 $8.93 $8.37 $7.87 $7.14 $7.12 $10.05 $11.16 $14.46 $12.90
Total Capital		 513 490 462 435 396 395 711 685 893 836
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -596 -559 -516 -472 -435 -436 -745 -702 -911 -851
Capital Expenditures (CapEx)		 1.25 0.37 4.01 11 8.08 12 7.40 4.69 -0.19 0.94
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -79 -59 -47 -37 -45 -55 -39 -47 -48 -46
Debt-free Net Working Capital (DFNWC)		 403 348 350 331 313 320 481 463 502 443
Net Working Capital (NWC)		 403 348 350 331 313 320 481 463 502 443
Net Nonoperating Expense (NNE)		 12 7.82 9.20 8.43 13 0.85 8.08 6.41 12 14
Net Nonoperating Obligations (NNO)		 -596 -559 -516 -472 -435 -436 -745 -702 -911 -851
Total Depreciation and Amortization (D&A)		 0.77 0.82 0.88 0.90 0.90 0.89 1.46 1.94 1.99 1.99
Debt-free, Cash-free Net Working Capital to Revenue		 -171.90% -126.20% -101.26% -71.17% -96.69% -70.31% -49.65% -52.73% -54.57% -98.24%
Debt-free Net Working Capital to Revenue		 876.59% 743.33% 749.13% 640.23% 667.14% 406.69% 605.84% 523.17% 573.51% 940.05%
Net Working Capital to Revenue		 876.59% 743.33% 749.13% 640.23% 667.14% 406.69% 605.84% 523.17% 573.51% 940.05%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.79) ($0.59) ($0.70) ($0.67) ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89)
Adjusted Weighted Average Basic Shares Outstanding		 54.54M 53.93M 58.19M 58.33M 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M
Adjusted Diluted Earnings per Share		 ($0.79) ($0.59) ($0.70) ($0.67) ($0.90) ($0.25) ($0.69) ($0.58) ($0.82) ($0.89)
Adjusted Weighted Average Diluted Shares Outstanding		 54.54M 53.93M 58.19M 58.33M 58.42M 58.37M 70.77M 73.06M 76.13M 75.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 54.86M 55.18M 55.31M 55.41M 55.49M 61.11M 61.36M 61.75M 64.77M 64.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -31 -27 -32 -30 -40 -14 -37 -36 -50 -57
Normalized NOPAT Margin		 -328.94% -167.56% -335.18% -183.90% -851.44% -28.23% -360.01% -138.98% -1,349.55% -764.52%
Pre Tax Income Margin		 -450.24% -216.03% -432.37% -234.96% -1,118.17% -30.01% -472.02% -163.98% -1,670.33% -956.88%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Kymera Therapeutics' Financials

When does Kymera Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Kymera Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Kymera Therapeutics' net income changed over the last 5 years?

Kymera Therapeutics' net income appears to be on an upward trend, with a most recent value of -$223.86 million in 2024, rising from -$41.25 million in 2019. The previous period was -$146.96 million in 2023.

What is Kymera Therapeutics's operating income?
Kymera Therapeutics's total operating income in 2024 was -$261.64 million, based on the following breakdown:
  • Total Gross Profit: $47.07 million
  • Total Operating Expenses: $308.71 million
How has Kymera Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Kymera Therapeutics' total revenue changed from $2.93 million in 2019 to $47.07 million in 2024, a change of 1,504.4%.

How much debt does Kymera Therapeutics have?

Kymera Therapeutics' total liabilities were at $142.42 million at the end of 2024, a 21.2% decrease from 2023, and a 73.6% increase since 2019.

How much cash does Kymera Therapeutics have?

In the past 5 years, Kymera Therapeutics' cash and equivalents has ranged from $31.00 million in 2020 to $120.26 million in 2024, and is currently $120.26 million as of their latest financial filing in 2024.

How has Kymera Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Kymera Therapeutics' book value per share changed from -43.81 in 2019 to 12.90 in 2024, a change of -129.5%.

Remove Ads

Related Companies

This page (NASDAQ:KYMR) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners
[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...
Colonial Metals | Sponsored
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
Elon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to Mars
Elon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...
InvestorPlace | Sponsored
America’s Retirement Accounts Are at Risk—Here’s Why
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
My friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...
Crypto Swap Profits | Sponsored